Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH3A1 | P30838 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | ALDH2 | P05091 | 3/20 | 0.60 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28533366 | 0.81 | ALDH3A1 (0.67) | ALDH3A1ALDH1A1ALDH2CHRM5CES1 | |
| SCHEMBL17286209 | 0.80 | ALDH3A1 (0.65) | ALDH3A1ALDH1A1ALDH2CHRM5CA12 | |
| SCHEMBL29220078 | 0.80 | ALDH3A1 (0.65) | ALDH3A1ALDH1A1ALDH2CHRM5CA12 | |
| SCHEMBL4625293 | 0.80 | ALDH3A1 (0.65) | ALDH3A1ALDH1A1ALDH2CHRM5CA12 | |
| SCHEMBL16048101 | 0.80 | ALDH3A1 (0.65) | ALDH3A1ALDH1A1ALDH2CHRM5CA12 | |
| SCHEMBL11150299 | 0.79 | ALDH1A1 (0.63) | ALDH3A1ALDH1A1ALDH2CHRM5 | |
| SCHEMBL11419367 | 0.78 | CES1 (0.71) | ALDH3A1ALDH1A1ALDH2BCHECES1 | |
| SCHEMBL29011260 | 0.78 | ALDH3A1 (0.62) | ALDH3A1ALDH1A1ALDH2CHRM5CA12 | |
| SCHEMBL16046979 | 0.78 | ALDH1A1 (0.62) | ALDH3A1ALDH1A1ALDH2CES1 | |
| SCHEMBL16044675 | 0.77 | ALDH3A1 (0.60) | ALDH3A1ALDH1A1ALDH2CHRM5CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020115700-A1 | Substituted indole compounds and methods of their use | CHIN ALLISON C (US) | 2002-08-22 | — | — | US | disclosed |
| US-6372742-B1 | TELOMERASE ENZYME INHIBITORS AND ANTICANCER AGENTS | GERON CORPORATION | 2002-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115700-A1 | Substituted indole compounds and methods of their use | TERT, INMT, POT1 | ALDH3A1 1508/4885ALDH1A1 722/4885ALDH2 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.